Then, we explored how CSN6 affects the stability of CDK9 and found that overexpression of CSN6 decreased the turnover rate of CDK9 in melanoma cells by using the de novo protein synthesis inhibitor cycloheximide (CHX, Sigma, USA) (Fig. 4D). Here, CDK9 is linked to melanoma.